{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:21Z","timestamp":1790949141067,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.adro.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T21:13:43Z","timestamp":1593033223000},"page":"761-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?"],"prefix":"10.1016","volume":"5","author":[{"given":"Sylvia S.W.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2020.06.011_bib1","doi-asserted-by":"crossref","unstructured":"Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 pandemic [e-pub ahead of print]. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6236. Accessed April 5, 2020.","DOI":"10.1001\/jama.2020.6236"},{"key":"10.1016\/j.adro.2020.06.011_bib2","doi-asserted-by":"crossref","unstructured":"Ning MS, McAleer MF, Jeter MD, et al. Mitigating the Impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19 [e-pub ahead of print]. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2020.05.037. Accessed April 5, 2020.","DOI":"10.1016\/j.radonc.2020.05.037"},{"key":"10.1016\/j.adro.2020.06.011_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fonc.2020.00648","article-title":"Coronavirus: Older persons with cancer in Italy in the COVID-19 pandemic","volume":"10","author":"Fratino","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib5","doi-asserted-by":"crossref","unstructured":"Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system [e-pub ahead of print]. Cancer Discovery. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0516. Accessed April 5, 2020.","DOI":"10.1158\/2159-8290.CD-20-0516"},{"key":"10.1016\/j.adro.2020.06.011_bib6","doi-asserted-by":"crossref","unstructured":"Zaorsky NG, Yu JB, McBride SM, et al. Prostate cancer radiotherapy recommendations in response to COVID-19. Adv Radiat Oncol. 2020;5:659-665.","DOI":"10.1016\/j.adro.2020.03.010"},{"key":"10.1016\/j.adro.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline","volume":"201","author":"Morgan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib10","first-page":"316","article-title":"The stereotaxic method and radiosurgery of the brain","volume":"102","author":"Leksell","year":"1951","journal-title":"Acta Chir Scand"},{"key":"10.1016\/j.adro.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/02841869409121782","article-title":"Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects","volume":"33","author":"Lax","year":"1994","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2217\/fon.15.160","article-title":"Single versus multiple session stereotactic body radiotherapy for spinal metastasis: The risk-benefit ratio","volume":"11","author":"Redmond","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0003-4975(02)04681-7","article-title":"Stereotactic radiosurgery for lung tumors: Preliminary report of a phase I trial","volume":"75","author":"Whyte","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.adro.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01243894-200610000-00008","article-title":"Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors","volume":"1","author":"Le","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib15","doi-asserted-by":"crossref","unstructured":"Lee P, Loo BW, Biswas T, et al. Local control after stereotactic body radiation therapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.045. Accessed April 5, 2020.","DOI":"10.1016\/j.ijrobp.2019.03.045"},{"key":"10.1016\/j.adro.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/JTO.0b013e318279155f","article-title":"Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States","volume":"8","author":"Daly","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-1-30","article-title":"Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases","volume":"1","author":"Fritz","year":"2006","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: A randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijrobp.2014.05.017","article-title":"30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer","volume":"90","author":"Videtic","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib22","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement [e-pub ahead of print]. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.001. Accessed April 5, 2020.","DOI":"10.1016\/j.radonc.2020.04.001"},{"key":"10.1016\/j.adro.2020.06.011_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.adro.2020.06.011_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/S1460396917000061","article-title":"Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: A single institution experience","volume":"16","author":"Ma","year":"2017","journal-title":"J Radiother Pract"},{"key":"10.1016\/j.adro.2020.06.011_bib25","first-page":"325","article-title":"Mortality following single-fraction stereotactic body radiation therapy for central pulmonary oligometastasis","volume":"4","author":"Ma","year":"2017","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.adro.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.cllc.2017.10.010","article-title":"Comparison of single- and three-fraction schedules of stereotactic body radiation therapy for peripheral early-stage non-small-cell lung cancer","volume":"19","author":"Ma","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijrobp.2011.10.071","article-title":"Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors","volume":"84","author":"Trakul","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cllc.2013.06.006","article-title":"Clinical outcomes of single dose stereotactic radiotherapy for lung metastases","volume":"14","author":"Osti","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clon.2015.01.004","article-title":"Comparison of single-fraction and multi-fraction stereotactic radiotherapy for patients with 18F-fluorodeoxyglucose positron emission tomography-staged pulmonary oligometastases","volume":"27","author":"Siva","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ijrobp.2019.03.035","article-title":"Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors","volume":"104","author":"Finazzi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phro.2020.05.002","article-title":"Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy","volume":"14","author":"Finazzi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib32","first-page":"81","article-title":"Synchronous non small cell lung cancer nodules treated with stereotactic body radiation therapy (SBRT)","volume":"3","author":"Kumar","year":"2014","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.adro.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/0284186X.2017.1295166","article-title":"Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy","volume":"56","author":"Tekatli","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib34","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.athoracsur.2015.04.113","article-title":"Stereotactic radiosurgery\/stereotactic body radiotherapy for recurrent lung neoplasm: An analysis of outcomes in 100 patients","volume":"100","author":"Pennathur","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.adro.2020.06.011_bib35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","article-title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","volume":"58","author":"Koong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib40","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","article-title":"Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/jco.2014.32.3_suppl.328","article-title":"Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience","volume":"32","author":"Moningi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semradonc.2017.02.005","article-title":"Integration of stereotactic body radiation therapy into the multidisciplinary management of pancreatic cancer","volume":"27","author":"Rosati","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib45","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: A single-institution experience","volume":"22","author":"Moningi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: A systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eucr.2014.05.011","article-title":"Stereotactic body radiotherapy for the treatment of renal tumors","volume":"2","author":"Hanzly","year":"2014","journal-title":"Urol Case Reports"},{"key":"10.1016\/j.adro.2020.06.011_bib50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2020.06.011_bib51","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2020.06.011_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU International"},{"key":"10.1016\/j.adro.2020.06.011_bib53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clon.2007.02.007","article-title":"Is the \u03b1\/\u03b2 value for prostate tumours low enough to be safely used in clinical trials?","volume":"19","author":"Da\u015fu","year":"2007","journal-title":"Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib56","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib57","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2020.06.011_bib59","first-page":"1","volume":"37","author":"Van As","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.adro.2020.06.011_bib60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2018.36.6_suppl.128","article-title":"Single-dose radiotherapy (SDRT) in the management of intermediate risk prostate cancer: Early results from a phase II randomized trial","volume":"36","author":"Greco","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13014-018-1112-0","article-title":"ONE SHOT - single shot radiotherapy for localized prostate cancer: Study protocol of a single arm, multicenter phase I\/II trial","volume":"13","author":"Zilli","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib64","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib65","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib66","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2020.06.011_bib67","first-page":"16","article-title":"Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic\u00a0abdominal and pelvic cancers: Short-term local control,\u00a0metabolic response, and toxicity","volume":"1","author":"Perkins","year":"2010","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib68","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.prro.2013.05.006","article-title":"Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases","volume":"4","author":"Owen","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clon.2017.11.010","article-title":"Single fraction stereotactic ablative body radiotherapy for oligometastasis: Outcomes from 132 consecutive patients","volume":"30","author":"Gandhidasan","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib70","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1159\/000491605","article-title":"Single-fraction stereotactic body radiotherapy for oligometastatic lymph node relapse in prostate cancer","volume":"41","author":"Loi","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.adro.2020.06.011_bib71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.adro.2020.06.011_bib72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2020.06.011_bib73","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: A randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.21037\/tlcr.2018.09.21","article-title":"Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease","volume":"8","author":"Ning","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.adro.2020.06.011_bib75","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7785\/tcrt.2012.500355","article-title":"Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases","volume":"13","author":"Filippi","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.adro.2020.06.011_bib77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2014.10.021","article-title":"Stereotactic body radiation therapy for oligometastases to the lung: A phase 2 study","volume":"91","author":"Nuyttens","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib78","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/0284186X.2018.1445285","article-title":"Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy","volume":"57","author":"Sharma","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12885-016-2227-z","article-title":"A randomised phase II trial of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung (TROG 13.01 SAFRON II)","volume":"16","author":"Siva","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib80","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","article-title":"Liver resection for colorectal metastases","volume":"15","author":"Fong","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib81","first-page":"826","article-title":"Roentgen therapy of hepatic metastases","volume":"71","author":"Phillips","year":"1954","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"10.1016\/j.adro.2020.06.011_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2017.02.004","article-title":"Stereotactic body radiotherapy for liver metastases","volume":"27","author":"Goodman","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/B:JORA.0000010880.40483.c4","article-title":"Radiosurgery for tumors in the body: Clinical experience using a new method","volume":"1","author":"Blomgren","year":"1998","journal-title":"J Radiosurg"},{"key":"10.1016\/j.adro.2020.06.011_bib84","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000078271","article-title":"Stereotactic radiation therapy of liver metastases: Update of the initial phase-I\/II trial","volume":"38","author":"Herfarth","year":"2004","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","article-title":"A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases","volume":"23","author":"Meyer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/B:JORA.0000010898.87146.2e","article-title":"Extracranial stereotactic radiosurgery of localized targets","volume":"1","author":"Lax","year":"1998","journal-title":"J Radiosurg"},{"key":"10.1016\/j.adro.2020.06.011_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1748-717X-8-175","article-title":"Single-dose radiosurgical treatment for hepatic metastases\u2014therapeutic outcome of 138 treated lesions from a single institution","volume":"8","author":"Habermehl","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib89","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib90","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib91","first-page":"45","article-title":"High versus low dose stereotactic body radiation therapy for hepatic metastases","volume":"20","author":"Kok","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib93","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib94","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.0300-0664.2001.01435.x","article-title":"Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital","volume":"56","author":"Lam","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.adro.2020.06.011_bib96","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/bjs.1800830432","article-title":"Adrenalectomy for metastatic disease to the adrenal glands","volume":"83","author":"Lo","year":"1996","journal-title":"Br J Surg"},{"key":"10.1016\/j.adro.2020.06.011_bib97","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity","volume":"3","author":"Toesca","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/COC.0000000000000634","article-title":"Novel dose escalation approaches for stereotactic body radiotherapy to adrenal oligometastases: A single-institution experience","volume":"43","author":"Figura","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib99","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.rpor.2015.05.009","article-title":"SBRT: A viable option for treating adrenal gland metastases","volume":"20","author":"Ippolito","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.adro.2020.06.011_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic body radiation therapy of adrenal metastases: A pooled meta-analysis and systematic review of 39 studies with 1006 patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib101","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/COC.0b013e3181dbb727","article-title":"Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer","volume":"34","author":"Oshiro","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib102","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ijrobp.2010.11.060","article-title":"Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience","volume":"82","author":"Casamassima","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fonc.2015.00185","article-title":"A retrospective review of CyberKnife stereotactic body radiotherapy for adrenal tumors (primary and metastatic): Winthrop University Hospital experience","volume":"5","author":"Desai","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib104","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/jcrt.JCRT_655_16","article-title":"Single institution experience treating adrenal metastases with stereotactic body radiation therapy","volume":"15","author":"Shah","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.adro.2020.06.011_bib105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/fon.10.165","article-title":"Stereotactic body radiation therapy for adrenal metastases: A retrospective review of a noninvasive therapeutic strategy","volume":"7","author":"Torok","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib106","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/fon-2020-0063","article-title":"The future of radiation-induced abscopal response: Beyond conventional radiotherapy approaches","volume":"16","author":"Tubin","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib107","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s10147-014-0717-z","article-title":"Radiobiological basis of SBRT and SRS","volume":"19","author":"Song","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/439752","article-title":"The confluence of stereotactic ablative radiotherapy and tumor immunology","volume":"2011","author":"Finkelstein","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.adro.2020.06.011_bib109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","article-title":"Assessing the interactions between radiotherapy and antitumour immunity","volume":"16","author":"Grassberger","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib111","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-019-5266-4","article-title":"Phase I\/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","volume":"19","author":"Bahig","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib112","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2020.06.011_bib113","doi-asserted-by":"crossref","first-page":"S696","DOI":"10.1016\/j.ijrobp.2014.05.2044","article-title":"Reduced lymphocytopenia following stereotactic body radiation therapy (SBRT) for spine metastases compared with conventional radiation therapy (CRT)","volume":"90","author":"Mian","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib114","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib116","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9691067","article-title":"Lymphopenia is associated with gross target volumes and fractions in hepatocellular carcinoma patients treated with external beam radiation therapy and also indicates worse overall survival","volume":"2019","author":"Zhang","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2020.06.011_bib117","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0167-8140(19)30697-8","article-title":"OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC","volume":"133","author":"Siva","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib118","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jama.2020.0400","article-title":"Radiation oncology alternative payment model","volume":"323","author":"Royce","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.adro.2020.06.011_bib119","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/j.ijrobp.2010.10.074","article-title":"Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer","volume":"81","author":"Sher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib121","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0360-3016(01)02822-X","article-title":"The effectiveness of\u00a0breath-holding to stabilize lung and pancreas tumors during\u00a0radiosurgery","volume":"53","author":"Murphy","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.011_bib122","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2019.07.021","article-title":"The transformation of radiation oncology using real-time magnetic resonance guidance: A review","volume":"122","author":"Hall","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2020.06.011_bib123","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/1754-9485.12968","article-title":"Magnetic resonance-guided radiation therapy: A review","volume":"64","author":"Chin","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.adro.2020.06.011_bib124","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.adro.2020.06.011_bib125","doi-asserted-by":"crossref","unstructured":"Finazzi T, Haasbeek CJA, Spoelstra FOB, et al. Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors [e-pub ahead of print]. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.02.025. Accessed April 5, 2020.","DOI":"10.1016\/j.ijrobp.2020.02.025"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420301603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420301603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:38:58Z","timestamp":1762529938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109420301603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2452109420301603"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2020.06.011","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}